BioSpace News Archive

Acasti Pharma Inc., a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, announced the appointment of Prashant Kohli as Acasti’s new Chief Executive Officer, succeeding Jan D’Alvise.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST), a late-stage, specialty pharma company advancing drug candidates for rare and orphan diseases, today announced that it received a Type C written meeting response and clarifying feedback from the United States Food and Drug Administration (FDA) on Acasti’s proposed Phase 3 Safety Study for GTX-104.

Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,464,749 to Microbion with claims to the use of Microbion’s proprietary pravibismane inhaled composition for treatment of pulmonary infections.

Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.

Otsuka Pharmaceutical Co., Ltd and H. Lundbeck A/S published results from research demonstrating that an investigational long-acting injectable, aripiprazole 2-month, ready-to-use 960 mg, offers comparable tolerability, safety and therapeutic plasma levels as aripiprazole 1-month, ready-to-use 400 mg, currently approved in adult patients for the treatment of schizophrenia or the maintenance treatment of bipolar I disorder.

Skanska has signed a contract amendment with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 124,300 shares, and restricted stock units covering an aggregate of 40,350 shares, of BioCryst common stock.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in a model of intracerebral hemorrhage (hemorrhagic stroke) demonstrating a behavioral outcome improvement at one month.

Horizon Therapeutics plc announced that it has been named one of Fortune’s 100 Best Companies to Work For® for the third consecutive year.

AiCuris Anti-infective Cures AG, a leading clinical stage pharmaceutical company in the development of novel, resistance-breaking anti-infective agents for the treatment of severe and potentially life-threatening infectious diseases, announced the appointment of Larry Edwards as Chief Executive Officer, effective April 1, 2023.